Synthesis and structure-activity relationship study of a potent MHO7 analogue as potential anti-triple negative breast cancer agent

• Published in: European journal of medicinal chemistry 2022-06, Vol.236, p.114313-114313, Article 114313
• Main Authors: Liang, Jian-Jia, Yu, Wu-Lin, Yang, Liang, Qin, Kong-Ming, Yin, Yu-Ping, Li, Dan, Ni, Yuan-Hao, Yan, Jing-Jing, Zhong, Yin-Xian, Deng, Zi-Xin, Hong, Kui
• Format: Article
• Language: English
• Subjects: Anti-metastasis; Apoptosis; G1 phase; Marine sesterterpene; TNBC
• ISSN: 0223-5234; 1768-3254
• DOI: 10.1016/j.ejmech.2022.114313

Triple-negative breast cancer (TNBC) is the most aggressive, high recurrence and metastatic breast cancer subtype. There are few safe and effective therapeutic drugs for treatment of TNBC. The marine natural product MHO7 has been determined to be a potential antitumor agent. However, its moderate activity and complex structure hampered its clinical application. In this study, a series of novel derivatives with modification on C24 of MHO7 were first synthesized. Some of the analogues were significantly more potent than MHO7 against all selected breast cancer cell lines. Among them, compound 4m had the best activity, and its IC50 value against TNBC was up to 0.51 μM. A whole-genome transcriptomic analysis shown that the mechanism of compound 4m against TNBC cells was similar with that of parent compound MHO7. Subsequent cellular mechanism studies showed that compound 4m could induce apoptosis of MDA-MB-231 cells through mitochondria pathway and cause G1 phase arrest. Moreover, 4m could disrupt the expressions of MAPK/Akt pathway-associated proteins (p-p38 and p-Akt) and remarkably increase the ratio of Bax to Bcl-2 and activate cleaved caspase 3/9/PARP. Importantly, 4m could influence the expression of Smad 7, and p-Smad 3 to inhibit TNBC cells metastasis. Stability assays in rat plasma and liver microsomes indicated that 4m still have room for further optimization. And the results of the online molinspiration software predicted that 4m has desirable physicochemical properties but some properties still have violation from the Lipinski rule of five. Overall, the modification on C24 of MHO7 was a promising way for developing novel anti-TNBC agents with considerable potential for optimization. [Display omitted] •Two series of novel anti-TNBC agents based on marine sesterterpene MHO7 have been discovered.•Compound 4m showed the best anti-proliferative activity against both drug-sensitive and drug-resistant cancer cells.•4m induced cell apoptosis of MDA-MB-231 cells through the ROS/p38/Akt/Bcl-2 pathway.•4m inhibited metastasis of MDA-MB-231 cells through TGF-β/Smad signaling pathway.